US-based Eli Lilly's Kisunla drug and Japanese company Eisai's Leqembi (below), two breakthrough drugs for the diagnosis and ...
Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...
RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...
Leerink 2025 Global Healthcare Conference March 10, 2025 9:20 AM ETCompany ParticipantsLucas Montarce - CFOMike Czapar ...
24/7 Wall St. on MSN5h
2 Stocks That Could Split Very SoonStock splits tend to create a lot of buzz in the market, especially when some of the most prominent companies announce a ...
ALIA-1758 is in the same general class as Eisai/Biogen's Leqembi (lecanemab) and Eli Lilly's Kisunla (donanemab), which have started to roll out in markets around the world but are seeing ...
Such tests are increasingly moving beyond their origins in cutting-edge research and into the laboratory and diagnostic mainstream.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback